Cargando…

Impact of COVID-19 on people with cystic fibrosis

Detalles Bibliográficos
Autores principales:	Colombo, Carla, Burgel, Pierre-Régis, Gartner, Silvia, van Koningsbruggen-Rietschel, Silke, Naehrlich, Lutz, Sermet-Gaudelus, Isabelle, Southern, Kevin W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159857/ https://www.ncbi.nlm.nih.gov/pubmed/32304639 http://dx.doi.org/10.1016/S2213-2600(20)30177-6

Ejemplares similares

Diabetes in Cystic Fibrosis: Multicenter Screening Results Based on Current Guidelines
por: Scheuing, Nicole, et al.
Publicado: (2013)

Getting Near to “Closing the Gap” in the Pediatric Age Group for the First Personalized Treatment of Cystic Fibrosis
por: van Koningsbruggen-Rietschel, Silke
Publicado: (2021)

High Variability in Oral Glucose Tolerance among 1,128 Patients with Cystic Fibrosis: A Multicenter Screening Study
por: Scheuing, Nicole, et al.
Publicado: (2014)

Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine
por: Pranke, Iwona, et al.
Publicado: (2019)

The Changing Face of Cystic Fibrosis and Its Implications for Screening
por: Naehrlich, Lutz
Publicado: (2020)

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020
por: Naehrlich, Lutz, et al.
Publicado: (2021)

Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis
por: Marsac, Charlotte, et al.
Publicado: (2021)

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
por: Regard, Lucile, et al.
Publicado: (2022)

Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?
por: Witko-Sarsat, V, et al.
Publicado: (1999)

Mycobacterium abscessus and Children with Cystic Fibrosis
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2003)

Sweat Chloride Testing and Nasal Potential Difference (NPD) Are Primary Outcome Parameters in Treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2021)

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis
por: De Rose, Virginia, et al.
Publicado: (2018)

Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function
por: Düesberg, Uta, et al.
Publicado: (2020)

Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy
por: Burgel, Pierre-Régis, et al.
Publicado: (2016)

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis
por: McClenaghan, Elliot, et al.
Publicado: (2020)

Proteomic profiling of sweat in patients with cystic fibrosis provides new insights into epidermal homoeostasis
por: Cornet, Matthieu, et al.
Publicado: (2022)

Moving the Dial on Airway Inflammation in Response to Trikafta in Adolescents with Cystic Fibrosis
por: Lepissier, Agathe, et al.
Publicado: (2023)

Reduced neutrophil elastase inhibitor elafin and elevated transforming growth factor-β(1) are linked to inflammatory response in sputum of cystic fibrosis patients with Pseudomonas aeruginosa
por: Thomassen, Jan C., et al.
Publicado: (2021)

β‐adrenergic sweat test in children with inconclusive cystic fibrosis diagnosis: Do we need new reference ranges?
por: Zampoli, Marco, et al.
Publicado: (2022)

The CF-CIRC study: a French collaborative study to assess the accuracy of Cystic Fibrosis diagnosis in neonatal screening
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2006)

COVID-19 vaccine prioritisation for people with cystic fibrosis
por: Carr, Siobhán B, et al.
Publicado: (2021)

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators
por: Fajac, Isabelle, et al.
Publicado: (2021)

The effect of TGF-β(1) polymorphisms on pulmonary disease progression in patients with cystic fibrosis
por: Trojan, T., et al.
Publicado: (2022)

Urinary Exosomes of Patients with Cystic Fibrosis Unravel CFTR-Related Renal Disease
por: Gauthier, Sebastien, et al.
Publicado: (2020)

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
por: Quittner, Alexandra, et al.
Publicado: (2015)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
por: Floto, R Andres, et al.
Publicado: (2016)

Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report.
por: Sermet-Gaudelus, I, et al.
Publicado: (1999)

Myeloperoxidase Promoter Polymorphism −463G Is Associated With More Severe Clinical Expression of Cystic Fibrosis Pulmonary Disease
por: Reynolds, Wanda F., et al.
Publicado: (2006)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
por: Floto, R Andres, et al.
Publicado: (2016)

In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2007)

Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France
por: Martin, Clémence, et al.
Publicado: (2021)

Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study
por: Bain, Robert, et al.
Publicado: (2021)

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures
por: van Koningsbruggen-Rietschel, Silke, et al.
Publicado: (2021)

Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry
por: Hatziagorou, Elpis, et al.
Publicado: (2023)

Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis
por: Marteyn, Benoît S., et al.
Publicado: (2017)

Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)
por: Sinha, Aditi, et al.
Publicado: (2021)

A Novel Lipidomic Strategy Reveals Plasma Phospholipid Signatures Associated with Respiratory Disease Severity in Cystic Fibrosis Patients
por: Guerrera, Ida Chiara, et al.
Publicado: (2009)

Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case–control study
por: Bagheri-Hanson, Azadeh, et al.
Publicado: (2014)

Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons
por: Pranke, Iwona, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gifd94corqk1bc6geemmqfoeqe